Timothy Arthur James Haystead

About

Timothy Arthur James Haystead is a Professor of Pharmacology and Cancer Biology at Duke University. He is also an Associate Professor in Pathology and a member of the Duke Cancer Institute. His roles involve leading research in pharmacology and cancer biology, contributing to the academic and scientific community at Duke. His primary faculty position is based at the Duke University Medical Center in Durham, North Carolina, where he is engaged in advancing understanding in his fields of expertise.

Research topics

• Biology
• Cell biology
• Medicine
• Cancer research
• Internal medicine
• Immunology
• Genetics
• Oncology
• Biochemistry
• Chemistry

Selected publications

• Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1

  Science Translational Medicine · 2020 · 85 citations

  gene was amplified, and nuclear HSF1 abundance was markedly increased in prostate cancers and particularly in neuroendocrine prostate cancer (NEPC), for which there are no available treatment options. Despite genetic validation of HSF1 as a therapeutic target in a range of cancers, a direct and selective small-molecule HSF1 inhibitor has not been validated or developed for use in the clinic. We described the identification of a direct HSF1 inhibitor, Direct Targeted HSF1 InhiBitor (DTHIB), which…

  DOI

• TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases

  Open Biology · 2020 · 54 citations

  Senior authorCorresponding

  Aberrant tumour necrosis factor (TNF) signalling is a hallmark of many inflammatory diseases including rheumatoid arthritis (RA), irritable bowel disease and lupus. Maladaptive TNF signalling can lead to hyper active downstream nuclear factor (NF)-κβ signalling in turn amplifying a cell's inflammatory response and exacerbating disease. Within the TNF intracellular inflammatory signalling cascade, transforming growth factor-β-activated kinase 1 (TAK1) has been shown to play a critical role in med…

  DOI

• The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect

  Nature Structural & Molecular Biology · 2021 · 37 citations

  DOI

• Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis

  JCI Insight · 2023-06-12 · 22 citations

  articleOpen access

  Multiorgan fibrosis in systemic sclerosis (SSc) accounts for substantial mortality and lacks effective therapies. Lying at the crossroad of TGF-β and TLR signaling, TGF-β-activated kinase 1 (TAK1) might have a pathogenic role in SSc. We therefore sought to evaluate the TAK1 signaling axis in patients with SSc and to investigate pharmacological TAK1 blockade using a potentially novel drug-like selective TAK1 inhibitor, HS-276. Inhibiting TAK1 abrogated TGF-β1 stimulation of collagen synthesis and…

  PublisherOA PDFDOI

• Selective targeting of Plasmodium falciparum Hsp90 disrupts the 26S proteasome

  Cell chemical biology · 2024-03-15 · 17 citations

  articleOpen access
  PublisherOA PDFDOI

Recent grants

• NIH Grant R01AI08952604

  NIH · $764k · 2015

• NIH Grant P01HL019242

  NIH · $25.4M · 2010

• NIH Grant R01DK052378

  NIH · $2.1M · 2006

Frequent coauthors

• Philip F. Hughes

  Duke University

  95 shared

• Justin A. MacDonald

  University of Calgary

  84 shared

• Christopher N. Fortner

  SUNY Upstate Medical University

  59 shared

• David R. Loiselle

  Duke University

  58 shared

• Thomas M. Coffman

  Duke-NUS Medical School

  55 shared

• Susan B. Gurley

  University of Southern California

  54 shared

• Matthew A. Sparks

  Georgetown University

  53 shared

• Thu H. Le

  University of Rochester Medical Center

  50 shared

Similar researchers at Duke University

• Christopher Bang Newgardh-175
• Donald Patrick McDonnellh-119
• Cynthia Moreton Kuhnh-110